The Business Research Company’s latest study espouses that the global infection prevention market is projected to escalate from $41.64 billion in 2023 to an estimated $43.40 billion in 2024, representing a compound annual growth rate (CAGR) of approximately 4.2%. This growth is predominantly driven by an increasing awareness of healthcare-associated infections (HAIs), strict regulatory guides, technological advancements, and rising healthcare expenditure. Despite potential impediments from global events, the market is on course to achieve a figure of nearly $50.21 billion by 2028.
The growing incidence of hospital-acquired infections (HAIs) has been a crucial driver of the infection prevention market. HAIs encompass infections patients contract during the course of receiving healthcare treatments. Strategies to prevent HAIs encompass strict hygienic practices, utilization of sterilization equipment, and disinfectors. For instance, in December 2023, the Australian Institute of Health and Welfare reported a significant 1,546 cases of Staphylococcus aureus bloodstream infections within hospitals, amplifying the need for effective infection prevention strategies.
Key players within the infection prevention market, such as Cardinal Health Inc., 3M Company, and Ecolab Inc., are honing their focus on innovation. Indeed, the development of infection preventionist staffing calculators to aid healthcare facilities in gauging optimal staffing levels, based on patient acuity levels and facility size, is part of this formative initiative, enhancing patient safety and promoting efficient infection control.
Trends shaping the global infection prevention market include the advent and adoption of telemedicine and digital health solutions, the development of personalized infection prevention strategies, the proliferation of artificial intelligence (AI) for expeditious diagnostics, and the execution of behavioral interventions to minimize infection risks.
The infection prevention market report segments include product (sterilization equipment, disinfectors, consumables), infection type (microbial infections, healthcare associated infections), and end users (hospitals and clinics, pharmaceutical companies, clinical laboratories, medical device companies, life science industry, and academic and research centers).
The North American region has previously dominated the infection prevention market in 2023, a success attributed to its robust healthcare infrastructure and rigorous regulatory standards. Unsurprisingly, the region continues to lead in terms of the adoption of advanced infection prevention technologies.
The Business Research Company’s comprehensive report provides a wealth of insights into the size of the infection prevention market, the major drivers, competitors’ revenues, market positioning, and growth across different geographical regions. This presents potential opportunities and strategies to companies looking to tap into segments presenting the highest growth potential.